

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTJUN 23 2004  
U.S. PATENT AND TRADEMARK OFFICE

(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	09/835,523
Filing Date	04/17/2001
First Named Inventor	Yong-Qian Wu
Group Art Unit	1624
Examiner Name	Truong, Tamthom Ngo
Attorney Docket Number	054707-0661

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
B.K.	A1	4,801,706		WINKLEY et al.	01/31/1989	
B.K.	A2	5,399,565		GREENWOOD et al.	03/21/1995	
B.K.	A3	5,670,503		KAWAI et al.	09/23/1997	
B.K.	A4	5,798,355		STEINER et al.	08/25/1998	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
B.K.	A5	CA	2,271,837	A1	ARZNEIMITTEL WERK DRESDEN GMBH, DE	11/11/1999		
B.K.	A6	EP	0 104 484	A1	NIPPON KAYAKU KABUSHIKI KAISHA	04/04/1984		
B.K.	A7	EP	0 450 757	A2	GLAXO GROUP LIMITED	10/09/1991		
B.K.	A8	EP	0 778 023	A1	AMERICAN HOME PRODUCTS CORPORATION	06/11/1997		
B.K.	A9	WO	89/06535	A1	E.R. SQUIBB & SONS, INC.	07/27/1989		
	A10	WO	94/19350	A1	FUJISAWA PHARMACEUTICAL CO., LTD.	09/01/1994		
B.K.	A11	WO	99/20272	A1	MERCK & CO., INC.	04/29/1999		
B.K.	A12	WO	96/05180	A1	ABBOTT LABORATORIES	02/22/1996		
B.K.	A13	WO	99/46248	A1	VERTEX PHARMACEUTICALS INCORPORATED	09/16/1999		
B.K.	A14	WO	98/05333	A1	MOLECUMETICS LTD	02/12/1998		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
B.K.	A15	BALDWIN et al., "Pyrazolotriazines: a new class of tumour-inhibitory agents," J. Pharm. Vol. 18, pp. 1S-4S (May 2, 1966).	
B.K.	A16	Borloo et al., "Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase," Letters in Peptide Science, vol. 2, pp. 198-202 (1995).	

Examiner Signature

Date Considered

10/1/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>JUN 23 2004</p> <p>(use as many sheets as necessary)</p>				<b>Complete if Known</b>	
<p>Sheet 1 of 2</p>				<p>Application Number</p> <p>Filing Date</p> <p>First Named Inventor</p> <p>Group Art Unit</p> <p>Examiner Name</p> <p>Attorney Docket Number</p>	<p>09/835,523</p> <p>04/17/2001</p> <p>Yong-Qian Wu</p> <p>1624</p> <p>Truong, Tamthom Ngo</p> <p>054707-0661</p>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
B.K.	A17	STEINER et al., "Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A," Nature Medicine, vol. 3, no. 4, pp. 421-428 (April 1997).	

Examiner Signature	<i>Brunch Kipp</i>	Date Considered	10/11/04
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.